Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by Volcom370on Mar 21, 2018 8:20am
196 Views
Post# 27751704

RE:RE:RE:RE:ATE.

RE:RE:RE:RE:ATE.Did you forget this part of information on purpose ? These rights could be worth way more than the 4M dollars profit they made on the shares. "Under the terms of the license agreement, Antibe has granted Knight the exclusive commercial rights for Antibes drug candidates and other future prescription drugs in Canada, Israel, Romania, Russia and sub-Saharan Africa"
porksniffer wrote:
rtftech16 wrote: If Knight converts the debentures and warrants it can have 2,272,727 shares at a bought price of $0.22/share from Antibe and 3,225,806 shares at a bought price of $0.31/share from Antibe. Looking at Antibe's share price today thats a nice profit. 



Oh wow!! Assuming a $1.00/share price for that penny stock, 5.5 million shares less the $1.5 million cost works out to a massive profit of................$3.5 million dolllars. What an investment! Should be enough for the company Christmas party. Hillarious how you get an erection for a couple million dollars. To remind you, market cap is over a billion here. You think this even registers?? Just stop posting, you keep embarrasing yourself.


Bullboard Posts